Search
HCW 26: Ovid Therapeutics CEO Meg Alexander highlights big progress the company has been making in neuroscience on its next-generation GABA-aminotransferase inhibitor and oral KCC2 direct activator
OV329, the GABA-AT inhibitor, will have photosensitivity data over the coming months while OV4071, the KCC2, will start a ketamine challenge study by the end of the year that should give visibility to a host of important biomarkers to better understand its profile. Coverage brought to you by
Sep 14
Ovid Therapeutics' new CEO Meg Alexander walks us through the company's lead programs in neurology
She discusses the GABA-aminotransferase inhibitor, OV329, and KCC2 programs.
Feb 2
Ovid's Jeremy Levin on advances in CNS, soticlestat, ROCK2, Washington and more
Jeremy Levin walks us through the science of Ovid's CNS-focused pipeline, gives his take on the health of the biotech.
Jan 22, 2024
.png){kind=logo}